New drug shows promise for Hard-to-Treat ovarian cancer
Disease control
Ongoing
This study tests a drug called CYH33 in people whose ovarian, fallopian tube, or peritoneal clear cell cancer has come back or not gone away. It is for those with a specific gene change (PIK3CA mutation) and who have already tried standard chemotherapy. The main goal is to see if…
Phase: PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:41 UTC